October 20, 2011
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer

Financial Disclosure for SymBio's New Listing on Osaka Securities Exchange JASDAQ Growth Market

Date of New Listing: The Company's common shares were listed on the Osaka Securities Exchange JASDAQ Growth Market on October 20, 2011.
Disclosure of the Company's financial forecast and financial results, originally reported on September 14th, 2011, are as follows.

【Financial Forecast】 (Unit : million JPY,%)

	Fiscal Year 2011 (Forecast)			Fiscal Year 2010 (Actual)			Second Quarter, Fiscal Year 2011 (Actual)	
		%	vs. PY		%	vs. PY		%
Net Sales	1,933	100.0	133.3	1,449	100.0	121.7	982	100.0
Operating Income	(2,351)	(121.6)	---	(612)	(42.3)	---	(701)	(71.4)
Ordinary Income	(2,398)	(124.1)	---	(638)	(44.0)	---	(700)	(71.2)
Net Income	(2,407)	(124.5)	---	(642)	(44.3)	---	(707)	(72.0)
Net Income per Share	(164.39 JPY)			(5,933.47JPY) [59.33JPY]			(53.56 JPY)	
Dividend per Share	0.00 JPY			0.00 JPY			0.00 JPY	

Note: 1. The Company does not have any subsidiaries to disclose consolidated financial statements.
2. Net income per share for the results of Fiscal Year 2010, and the Second Quarter, Fiscal Year 2011, was calculated using the average number of outstanding shares. However, net income per share for the financial forecast of Fiscal Year 2011, was calculated using the estimated average number of outstanding shares including the increase in number of shares for IPO (i.e. 5,100,000 shares) due to third party allotment and over-allotment (765,000 shares at maximum), and execution of stock options.
3. The company carried out a stock split (100 shares per share) on June 2, 2011. Figures in [ ] represent net income per share in case of this stock split being considered retroactively.

[Contact]
Hiroki Maekawa
Board Director, Corporate Officer, Chief Financial Officer
Tel: +081(0)3 5472 1125

October 20, 2011

Financial Results for the Second Quarter of Fiscal Year Ended December 31, 2011

Company Name: SymBio Pharmaceuticals Limited
(URL http://www.symbiopharma.com/)
Security Code: 4582
TEL: +81-3-5472-1125
President/ Representative Director and Chief Executive Officer: Fuminori Yoshida
Inquiries/ Board Director and Chief Financial Officer: Hiroki Maekawa

(Millions of Yen - rounded down unless otherwise stated)

1. Financial Results for the Second Quarter of Fiscal Year 2011 (January 1 to June 30)

(1) Financial Results (Cumulative)

	Net Sales		Operating Income		Ordinary Income		Quarterly Net Income	
		%		%		%		%
2nd Quarter FY 2011	982	—	(701)	—	(700)	—	(707)	—
2nd Quarter FY 2010	—	—	—	—	—	—	—	—

	Quarterly Net Income per Share(Yen)	Diluted Quarterly Net Income per Share(Yen)
2nd Quarter FY 2011	(53.56)	—
2nd Quarter FY 2010	—	—

Note:
1. Despite the issuance of new share subscription rights, information in connection with diluted quarterly net income per share will not be disclosed due to quarterly net loss per share.
2. As quarterly disclosure of financial results began 1st quarter FY 2011, prior financial information is not included in the above chart.

(2)Financial Position

	Total Assets	Net Assets	Equity Ratio (%)	Shareholders' Equity per Share(Yen)
2nd Quarter FY 2011	6,105	5,375	88.1	383.13
FY 2010	4,262	4,083	95.8	36,541.74

Note:
1. Shareholders' equity 2Q FY 2011: 5,375 mil Yen, FY 2010: 4,083 mil Yen
2. The Company carried out a stock split (100:1) on June 2nd, 2011

2. Dividends

	Dividend Per Share (Yen)				
(Date of Record)	1st Quarter	2nd Quarter	3rd Quarter	Fiscal Year End	Full Year
FY 2010	—	0.00	—	0.00	0.00
FY 2011	—	0.00			
FY 2011 (Forecast)			—	0.00	0.00

Note:
1. Revision of forecast for dividends in this quarter: No

3. Forecast of Financial Results for Fiscal Year 2011 (January 1 to December 31)

	Net Sales	Operating Income	Ordinary Income	Net Income	Net Income per Share (Yen)
	%	%	%	%	
Full Year	1,933 33.4	(2,351) —	(2,398) —	(2,407) —	(164.39)

Note:

1. Revision of this quarterly forecast: No
2. Figures calculated above include the increase in shares from initial public offering in FY 2011; Increase in shares due to overallotment is not included

4. Other Information

Note: For further details, please refer to “2. Other Information” in attachments.

(1) Simplified accounting treatment: Not applied

(2) Change in accounting rules, procedures and representation method in relation to the preparation of quarterly financial statements:

1. Changes in accounting principles: Yes
2. Changes other than (1): No

(3) Number of issued shares (common shares):

1. Number of issued shares at the end of period (including treasury shares)
   Second quarter of FY 2011: 14,030,900 shares, FY 2010: 111,737 shares
2. Number of treasury shares at the end of period
   Second quarter of FY 2011: - shares, FY 2010: - shares
3. Average number of shares during this period (quarterly cumulative period)
   Second quarter of FY 2011: 13,205,700 shares, Second quarter in FY 2010: - shares

Note: The Company carried out a stock split (100:1) on June 2nd, 2011

Information regarding proper use of financial forecasts, and other important matters

The aforementioned forecasts are estimates made by the Company based on information available at the time, and are subject to risks and uncertainties. Actual results may differ substantially from such forecasts due to various factors. Please refer to “Forecast of Business Results for Fiscal Year 2011” in Attachments.

[Attachments]

1. Financial Results Analysis, Financial Statements

(1) Financial Results Analysis

Financial status of the Company until the end of Second Quarter of FY 2011 is as follows:

1. Japan

In Japan, the oncology drug SyB L-0501 (generic name: bendamustine hydrochloride) received an NHI price on December 10, 2010, and was launched under the product name TREAKISYM® by the Company's business partner, Eisai Co., Ltd (Eisai). Approved indications of the drug are the treatment of patients with indolent B-cell non-Hodgkin's lymphoma (NHL) and mantle cell lymphoma (MCL). Since its launch in Japan, TREAKISYM® continues to show healthy growth in sales.

The Company is capitalizing on this "pipeline within a molecule" as it pursues additional indications with larger patient numbers. In Japan and Korea, the joint phase II clinical trial of SyB L-0501 for relapsed aggressive NHL is ongoing. In Japan, the phase II clinical trial of SyB L-0501 for the treatment of patients with untreated multiple myeloma is also underway.

In order to improve the life-cycle management of TREAKISYM®, development of indications beyond those currently under development is being considered.

The phase II clinical trial of the Company's second drug candidate, SyB D-0701 (transdermal antiemetic patch containing granisetron) for the treatment of radiotherapy-induced nausea and vomiting was initiated.

With regards to the third oncology drug candidate, SyB 0702 (polyethylene glycol-conjugated zinc protoporphyrin) and Hsp32 inhibitor, pre-clinical studies to support the initiation of a Phase I clinical trial are underway.

The development of SyB 0702 was accepted by NEDO (New Energy and Industrial Technology Development Organization) as an anticancer development project eligible to receive government support. NEDO publicly seeks projects for technological development by R&D venture businesses that meet its criteria as an innovation advancement project, and provided funding for a portion of the Company's development costs until February, 2011.

SyB L-1001 (generic name: forigerimod) for the treatment of systemic lupus erythematosus (SLE) have been initiated, however at present development has been suspended

. 2. Overseas

SyB L-0501 is being marketed by Eisai in Singapore and South Korea. In Singapore, the drug has been approved as first line treatment of patients with chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL), with sales continuing to increase steadily and remaining on track. In South Korea, the drug has recently been launched after receiving marketing approval from the Korea Food and Drug Administration (KFDA) for the treatment of patients with first line chronic lymphocytic leukemia and multiple myeloma. Under the License Agreement, the Company receives milestone payments from Eisai upon receipt of marketing approval.

In Taiwan, the Company's business partner, InnoPharmax Inc., is undertaking drug development of SyB-0501. At the end of the Second Quarter of FY 2011, InnoPharmax initiated post-NDA filing discussions with the Taiwan Food and Drug Administration in order to secure marketing approval.

3. Financial Results

As a result of these activities, total sales revenue was 982,651 thousand yen. Combined sales of SyB L-0501 in Japan and Singapore, together with the milestone payment resulting from the granting of marketing approval in South Korea, account for the revenue.

Sales and general administrative costs totaled 1,037,184 thousand yen. The R&D expenditure posted was 660,383 thousand yen, mainly comprising: the costs of clinical trials and preparations for all indications of SyB L-0501, clinical trial costs of SyB D-0701, and pre-clinical study costs of SyB 0702. Other sales and general administrative costs amounted to 376,800 thousand yen.

Thus, for the Second Quarter, the operating loss was 701,333 thousand yen. The NEDO grant and other non-operating revenues totaled 53,553 thousand yen. However, non-operating expenses due to losses incurred as a

result of currency fluctuations and other factors totaled 52,329 thousand yen, leading to an ordinary loss of 700,109 thousand yen. Net loss after tax was recorded as 707,340 thousand yen.

(2) Financial Position Analysis

1.Financial Position

Total assets as of March 31, 2011, stood at 6,105,153 thousand yen, an increase of 1,842,369 thousand yen compared to the previous financial year end (March 31, 2010). Current assets stood at 6,053,147 thousand yen, an increase of 1,840,347 thousand yen compared to the previous financial year end. This is the result of new shares being issued through third-party allocation, thereby increasing cash and cash deposits. A portion of the capital raised was switched to low-risk securities. Fixed assets increased by 2,022 thousand yen, up to 52,005 thousand yen,

Total liabilities stood at 729,455 thousand yen, with an increase of 549,736 thousand yen compared to the previous financial year end. Current liabilities totaled 727,420 thousand yen, an increase of 549,536 over the previous financial year end, mainly due to an increase in accounts payable arising from an increase in sales of TREAKISYM® as well as a short-term loan taken out for the payment thereof. Fixed liabilities at the end of this Second Quarter were posted as 2,035 thousand yen, solely in retirement benefit reserves.

Net assets increased to 5,375,697 thousand yen, up by 1,292,633 thousand yen compared to the previous financial year end. Despite net loss after tax totaling 707,340 thousand yen due to loss carried forward (negative profit surplus), new shares were issued through third party allocation which resulted in an increase of 1,000,020 thousand yen in capital stock and capital reserves, increasing capital to 4,710,850 thousand yen and capital reserves to 4,680,850 thousand yen. Capital-to-asset ratio decreased to 88.1% by 7.7% compared to the previous financial year end.

2. Cash Flow

Cash and cash equivalents (cash) at the end of the Second Quarter of FY 2011 increased to 5,317,891 thousand yen, a rise of 1,402,126 thousand yen over the previous financial year end.

The following is a breakdown of the cash flow position and factors prevailing in the Second Quarter of FY 2011.

<Cash Flow from Operating Activities>

The cash flow from operating activities was recorded as a negative balance of 824,355 thousand yen. Despite purchasing liabilities increasing by 245,165 thousand yen and debt service increasing by 64,196 thousand yen, a pre-tax net loss for the quarter of 705,440 thousand was posted, and inventory and accounts receivable increased by 236,176 thousand yen and 174,481 thousand yen respectively in line with increased sales of TREAKISYM®. Cash also decreased due to an increase in prepaid expenses of 11,502 thousand yen.

<Cash Flow from Investment Activities>

Cash flow from investment activities ended with a negative balance of 13,099 thousand yen. This was mainly due to the acquisition of software at a cost of 10,940 thousand yen.

<Cash Flow from Financing Activities>

Cash flow from financing activities was recorded as a positive balance of 2,243,039 thousand yen. This was mainly due to 2,000,040 thousand yen raised through new stock issuance through third party allocation, and 250,000 thousand yen short-term loan borrowed for the payment of purchasing liabilities of TREAKISYM®.

(3) Forecast of Financial Results for Fiscal Year 2011

Progress in pipeline development will lead to greater R&D expenditures, resulting in a rise of sales and general administrative costs to 3,021 million yen, a significant increase on a year-on-year basis. The development plan for each pipeline product are outlined below.

<SyB L-0501>

The phase II clinical trial of SyB L-0501 for the treatment of patients with relapsed aggressive NHL will continue, as will the Phase II clinical trial in patients with untreated multiple myeloma. Preparations will be undertaken for the development of the drug for untreated indolent NHL. To extend the life-cycle management of SyB L-0501, development of additional indications will be further considered.

<SyB 1101>

On July 7, 2011, the Company signed a License Agreement with Onconova Therapeutics, Inc., a private biopharmaceutical company located in Newtown, PA and Princeton NJ, USA, acquiring exclusive development and marketing rights in Japan and South Korea for the oncology drug SyB 1101 (generic name: rigosertib). In accordance with this Agreement, the Company is preparing for initiation of the Phase I clinical trial for the treatment of patients with relapsed aggressive myelodysplastic syndrome (MDS).

<SyB D-0701>

The phase II clinical trial for radiotherapy-induced nausea and vomiting will continue.

<SyB 0702>

Based on the results of pre-clinical studies conducted with some funding from NEDO, the next stage of development activities will be considered further.

In terms of profits, TREAKISYM®, launched in Japan on December 10, 2010, is expected to begin generating significant revenue. In its partnership with Eisai Co., Ltd., which is responsible for selling this product in Japan, the Company will continue to drive sales upward.

In Asia, sales revenues from SyB L-0501 in Singapore and South Korea are expected under the sales and marketing activities of Eisai (Singapore) Pte. Ltd. and Eisai Korea Inc., respectively. In Taiwan, marketing approval is under application, and the Company's business partner, InnoPharmax Inc., expects to begin booking sales before the end of 2011.

Given this outlook, the forecast for the fiscal year ending on March 31, 2012 is as follows: sales of 1,922 million yen, operating loss of 2,458 million yen, ordinary loss of 2,509 million yen, and current net loss of 2,518 million yen.

2. Other Information

(1) No simplified accounting or special accounting methods were used for the compilation of quarterly financial statements

(2) Changes have taken place in principles, procedures and presentation methods used in accounting for the compilation of quarterly financial statements

Application of accounting standards relating to asset retirement obligations:

Starting from the First Quarter of FY 2011, Accounting Standards Relating to Asset Retirement Obligations (Corporate Accounting Standards No. 18: March 31, 2008) and the Application Guideline for Accounting Standards Relating to Asset Retirement Obligations (Corporate Accounting Standards Application Guideline No. 21: March 31, 2008) have been applied.

This has resulted in an increase of 908 thousand yen in operating loss and ordinary loss for the First Half of FY 2011 (Q1 + Q2), and an increase of 6,239 thousand yen in pre-tax net loss and current net loss for the Second Quarter. Furthermore, the application of this accounting standard has resulted in a decrease of 5,331 thousand yen in "deposits and guarantees" for investment and other assets.

(3) No significant event has occurred regarding the going concern of the Company.

3. Quarterly Financial Statements
(1) Quarterly Balance Sheet

(Unit: Thousands of Yen)

	As of June 30, 2011	As of December 31, 2010
Assets		
Current Assets		
Cash & Deposits	2,816,341	2,314,484
Accounts Receivable	180,415	5,934
Valuable Securities	2,602,049	1,701,323
Inventories	236,176	—
Prepaid Expenses	102,250	101,905
Advances	81,404	86,081
Other Current Assets	34,508	3,070
Total Current Assets	6,053,147	4,212,800
Fixed Assets		
Tangible Fixed Assets		
Building (Net)	2,550	2,631
Fixtures & Equipment (Net)	17,493	19,295
Total Tangible Fixed Assets	20,044	21,927
Intangible Fixed Assets		
Software	10,821	772
Total Intangible Fixed Assets	10,821	772
Investments & Other Assets		
Security Deposits	21,140	27,282
Total Investments & Other Assets	21,140	27,282
Total Fixed Assets	52,005	49,982
Total Assets	6,105,153	4,262,783

(Unit: Thousands of Yen)

	As of June 30, 2011	As of December 31, 2010
Liabilities		
Current Liabilities		
Accounts Payable	246,333	1,168
Accounts Payable -other	188,519	124,323
Short Term Loan	250,000	—
Income Tax Payable	11,761	10,702
Other Current Liabilities	30,806	41,690
Total Current Liabilities	727,420	177,884
Long-Term Liabilities		
Accrued Retirement Benefits	2,035	1,835
Total Long-Term Liabilities	2,035	1,835
Total Liabilities	729,455	179,719
Net Assets		
Shareholders' Equity		
Capital Stock	4,710,850	3,710,830
Capital Surplus	4,680,850	3,680,830
Earned Surplus	(4,015,918)	(3,308,577)
Total Shareholders' Equity	5,375,781	4,083,082
Appraisal and Conversion Variance, etc.		
Other Valuable Securities Appraisal Variance	(84)	(18)
Total Appraisal and Conversion Variance, etc.	(84)	(18)
Total Net Assets	5,375,697	4,083,064
Total Liabilities and Net Assets	6,105,153	4,262,783

(2) Quarterly Income Statement

(Unit: Thousands of Yen)

	Second Quarter Fiscal Year 2011 January 1, 2011 to June 30, 2011
Net Sales	982,651
Cost of Sales	646,800
Gross Profit	335,850
Selling, General and Administrative Expenses	1,037,184
Operating Loss	701,333
Total Non-Operating Income	53,553
Total Non-Operating Expense	52,329
Ordinary Loss	700,109
Total Extraordinary Expense	5,331
Net Loss before Tax	705,440
Income Tax Total	1,900
Net Loss	707,340

(3) Quarterly Cash Flow Statements

(Unit: Thousands of Yen)

	Second Quarter Fiscal Year 2011 January 1, 2011 to June 30, 2011
Cash Flow from Operating Activities	
Net Loss before Tax	(705,440)
Depreciation Expense	3,941
Other Depreciation Expenses	1,194
Loss on adjustment for changes of accounting standard for asset retirement obligations	5,331
Increase in Accrued Retirement Benefits	200
Interest Income	(1,641)
Interest Expense	586
Foreign Exchange Loss	3,374
New Share Issuing Expense	7,000
Commission paid	11,157
Increase in Accounts Receivable	(174,481)
Increase in Inventories	(236,176)
Increase in Prepaid Expense	(11,502)
Decrease in Advances	4,676
Increase in Other Current Assets	(31,437)
Increase in Account Payable	245,165
Increase in Account Payable –other	64,196
Decrease in Other Current Liabilities	(9,824)
Others	226
Subtotal	(823,454)
Interest and Dividends Received	1,585
Interest Expenses Paid	(586)
Income Tax Paid	(1,900)
Net Cash Used by Operating Activities	(824,355)

(Unit: Thousands of Yen)

	Second Quarter Fiscal Year 2011 January 1, 2011 to June 30, 2011
Cash Flow from Investing Activities	
Payment for Purchase of Securities	(100,610)
Securities Redemption Revenue	100,000
Payment for purchase of tangible fixed assets	(1,167)
Payment for purchase of intangible fixed assets	(10,940)
Payment for other investments	(432)
Proceeds from investments and other assets	50
Net Cash Used by Investing Activities	(13,099)
Cash Flow from Financing Activities	
Increase in Short-Term Loans	250,000
Proceeds from Issuance of New Stock	2,000,040
Payment for Issuance of New Stock	(7,000)
Net Cash Provided by Financing Activities	2,243,039
Effect of Foreign Exchange Rate Changes on Cash and Cash Equivalents	(3,458)
Net Increase (Decrease) in Cash and Cash Equivalents	1,402,126
Cash and Cash Equivalents at the Beginning of the Period	3,915,765
Cash and Cash Equivalents at the End of the Period	5,317,891

(4) Business Continuity

Not applied.

(5) Segment Information

Segment information was not included as our business is a single business unit, namely drug research & development, manufacturing & sales, and other related activities.

(Additional Information)

Since this quarter, the Accounting Standards Relating to Segment Information Disclosure (Corporate Financial Reporting Standards No.17: March 27, 2009) and the Guideline for the Application of Accounting Standards Relating to Application of Accounting Standards for Segment Information Disclosure (Corporate Financial Reporting Standards Application Guideline No. 20: March 21, 2008) have been applied.

(6) Explanatory note concerning significant fluctuations in Shareholders' Equity

The resolution was passed at Board of Directors meeting held on February 14, 2011, with respect to third party allotment of 1,988,000 thousand yen (70,000 yen per stock), and the Company completed the process by February 25, 2011.

The resolution was passed at the Board of Directors meeting held on March 30, 2011, with respect to third party allotment of 12,040 thousand yen (70,000 yen per stock), and the Company completed the process by April 26, 2011. As a result, Capital Stock amounted to 4,710,850 thousand yen, and Capital Reserve amounted to 4,680,850 thousand yen.

(7) Important Subsequent Event

The Company signed a License Agreement with Onconova Therapeutics, Inc., a private biopharmaceutical company located in Newtown, PA and Princeton NJ, USA, acquiring exclusive development and marketing rights in Japan and South Korea for the oncology drug SyB 1101 (generic name: rigosertib) on July 7, 2011.